David A. Siegel Next Cure, Inc. Transaction History

Two Sigma Advisers, LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.03 - $1.45 $515 - $725	-500 Reduced 0.86%	57,700 $65,000
Q3 2023 Nov 14, 2023	SELL	$1.29 - $1.84 $20,640 - $29,440	-16,000 Reduced 21.56%	58,200 $75,000
Q2 2023 Aug 14, 2023	SELL	$1.47 - $1.86 $47,922 - $60,636	-32,600 Reduced 30.52%	74,200 $133,000
Q1 2023 May 15, 2023	SELL	$1.46 - $1.83 $51,830 - $64,965	-35,500 Reduced 24.95%	106,800 $158,000
Q4 2022 Feb 14, 2023	SELL	$1.2 - $3.07 $13,080 - $33,463	-10,900 Reduced 7.11%	142,300 $200,000
Q3 2022 Nov 14, 2022	BUY	$2.72 - $5.19 $134,912 - $257,424	49,600 Added 47.88%	153,200 $421,000
Q2 2022 Aug 15, 2022	BUY	$3.38 - $5.27 $338 - $527	100 Added 0.1%	103,600 $487,000
Q1 2022 May 16, 2022	SELL	$4.76 - $6.24 $263,704 - $345,696	-55,400 Reduced 34.86%	103,500 $503,000
Q4 2021 Feb 14, 2022	SELL	$5.7 - $9.1 $228,570 - $364,910	-40,100 Reduced 20.15%	158,900 $953,000
Q3 2021 Nov 15, 2021	BUY	$6.74 - $8.02 $698,264 - $830,872	103,600 Added 108.6%	199,000 $1.34 Million
Q2 2021 Aug 16, 2021	SELL	$7.6 - $10.28 $139,840 - $189,152	-18,400 Reduced 16.17%	95,400 $766,000
Q1 2021 May 17, 2021	BUY	$9.81 - $13.88 $277,623 - $392,804	28,300 Added 33.1%	113,800 $1.14 Million
Q4 2020 Feb 16, 2021	SELL	$9.47 - $12.43 $831,466 - $1.09 Million	-87,800 Reduced 50.66%	85,500 $932,000
Q3 2020 Nov 16, 2020	BUY	$8.15 - $21.17 $1.16 Million - $3.02 Million	142,600 Added 464.5%	173,300 $1.53 Million
Q2 2020 Aug 14, 2020	BUY	$21.19 - $40.2 $650,533 - $1.23 Million	30,700 New	30,700 $658,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $26.9M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.